Creative Life Science Co Ltd

As of June 30, 2026, Creative Life Science Co Ltd carries a market capitalization of 2.10B, placing it among publicly traded companies globally. Its enterprise value stands at 2.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Creative Life Science Co Ltd has 22.80M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Creative Life Science Co Ltd maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Creative Life Science Co Ltd's stock has declined approximately 28.51% over the past 52 weeks. The 50-day moving average sits at 78.90, while the 200-day moving average is 100.40.

As of June 30, 2026, Creative Life Science Co Ltd holds 284.39M in cash and equivalents against 322.67M in total debt, resulting in a net debt position of -97.59M. Total book value stands at 747.19M, with working capital of 195.02M providing operational flexibility.